-
Mashup Score: 16The Bone-Marrow Transplant Revolution - 14 hour(s) ago
Finding a matched donor has always been the major challenge. A drug has solved that problem.
Source: www.theatlantic.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13The Bone-Marrow Transplant Revolution - 15 hour(s) ago
Health Finding a matched donor has always been the major challenge. A drug has solved that problem. April 18, 2024 In the fall of 2021, Gabriel Arias felt like his body was “rotting from the inside.” He was diagnosed with acute myeloid leukemia, a form of blood cancer so aggressive that doctors had him hospitalized the day of his biopsy. In cases like his, the ideal treatment is a transplant. Arias’s cancer-prone blood cells needed to be destroyed and replaced with healthy ones taken from the
Source: apple.newsCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16The Bone-Marrow Transplant Revolution - 1 day(s) ago
Finding a matched donor has always been the major challenge. A drug has solved that problem.
Source: www.theatlantic.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16The Bone-Marrow Transplant Revolution - 2 day(s) ago
Finding a matched donor has always been the major challenge. A drug has solved that problem.
Source: www.theatlantic.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD - 25 day(s) ago
T-reg graft plus single-agent prophylaxis is preferred over T-reg graft alone for the prevention of acute GVHD.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation - 25 day(s) ago
Young adults (aged 18-25 years) are a distinct population with high rates of VOD.Disease-related factors predict for VOD in young adults (aged 18-25 years), and
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA - 25 day(s) ago
High-risk, untreated transplant-associated thrombotic microangiopathy after HCT has a dismal outcome due to multi-organ dysfunction.Early therapy with the C5 bl
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure for a variety of hematologic malignancies [1]. Historically, the availability of an HLA-matched donor was required for successful outcomes of HCT, to minimize the risk of graft rejection, graft-versus-host disease (GVHD), and nonrelapse mortality (NRM). An HLA-matched sibling donor (MSD) is the preferred donor, but this donor option is available in only 30% of patients [2]. In the absence of an MSD, an HLA-matched unrelated donor (MUD) may be identified through volunteer donor databases.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure for a variety of hematologic malignancies [1]. Historically, the availability of an HLA-matched donor was required for successful outcomes of HCT, to minimize the risk of graft rejection, graft-versus-host disease (GVHD), and nonrelapse mortality (NRM). An HLA-matched sibling donor (MSD) is the preferred donor, but this donor option is available in only 30% of patients [2]. In the absence of an MSD, an HLA-matched unrelated donor (MUD) may be identified through volunteer donor databases.
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 - 1 month(s) ago
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Some sobering numbers “ Two-thirds of white people can find a fully matched registry donor, but that number drops to 23 percent for Black Americans and 41 percent for Asians or Pacific Islanders We need more donors to join @CanadasLifeline #bmtsm https://t.co/oXepkiezRG